TICKERNERD
Menu
INKTINKTHealthcare · Biotechnology

INKT Stock Forecast: MiNK Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 12 Aug 2026
$12
+2.76% on the day

The 2 Wall Street analysts covering MiNK Therapeutics, Inc. hold a median 12-month price target of $39 — +238.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 38 of 100 as at 12 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$55.8M
Ticker Nerd rank
38 / 100
Median analyst target
$39
Analysts covering
2
Total return, dividends reinvested
1W
−1.4%
1M
+4.4%
YTD
+3.5%
1Y
−18.7%
From 52W high
−34.1%
From 52W low
+34.8%
$9
$18
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

INKT stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores MiNK Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Aug 2026
38 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
83
Size
81
Issuance
72
Revisions
47
Momentum
40
Value
33
Growth
18
Quality
18
Volatility
15

Accruals (83): Reported profit is backed by cash, and the company is not expanding recklessly.

Volatility (15): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

INKT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on INKT, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$20$30$40$50Oct 25Jan 26Apr 26Jul 26INKTHigh $43Median $39Low $35

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says2 analysts
2 Buy0 Hold0 Sell
Low $35Median $39High $43

The green dot is the last close — the median target sits +238.0% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
18 May 2026HC Wainwright & Co.ReiteratesBuy$35
1 Apr 2026HC Wainwright & Co.ReiteratesBuy—
15 Aug 2025HC Wainwright & Co.UpgradeBuy—
15 July 2025HC Wainwright & Co.DowngradeNeutral—
14 July 2025William BlairDowngradeMarket Perform—
18 Mar 2025HC Wainwright & Co.ReiteratesBuy—
25 Feb 2025HC Wainwright & Co.MaintainsBuy—
15 Nov 2024BairdMaintainsOutperform—
15 Nov 2024HC Wainwright & Co.ReiteratesBuy—
9 Oct 2024HC Wainwright & Co.ReiteratesBuy—
13 Aug 2024HC Wainwright & Co.ReiteratesBuy—
14 May 2024HC Wainwright & Co.ReiteratesBuy—
21 Mar 2024HC Wainwright & Co.MaintainsBuy—
10 Aug 2023HC Wainwright & Co.ReiteratesBuy—
12 May 2023HC Wainwright & Co.MaintainsBuy—
19 Apr 2023HC Wainwright & Co.ReiteratesBuy—
22 Mar 2023Evercore ISI GroupMaintainsOutperform—
22 Mar 2023HC Wainwright & Co.ReiteratesBuy—
10 Aug 2022HC Wainwright & Co.InitiatesBuy—
24 Jan 2022B. Riley SecuritiesMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. INKT appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

INKT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

MiNK Therapeutics, Inc. (INKT) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−3.8×

Cheaper than 88% of US stocks

Price / sales
—
Price / book
−4.2×

Cheaper than 96% of US stocks

EV / EBITDA
−3.5×

Cheaper than 76% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 33% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
87.8%

Higher than 95% of US stocks

Return on assets
−110.9%

Higher than 2% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

INKT vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
INKTMiNK Therapeutics, Inc.$55.8M
38
INMBINmune Bio, Inc.$54.2M
49
XLOXilio Therapeutics, Inc.$59.5M
71
EXOZeXoZymes, Inc.$53.5M
13
VRXAVERAXA Biotech AG$59.8M
40
ATYRaTyr Pharma, Inc.$53.0M
53
HYFTMindWalk Holdings Corp.$61.2M
59

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own MiNK Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest INKT news & analysis

MiNK Therapeutics Reports Second Quarter 2026 Financial Results and Reports Observations from Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury

GlobeNewsWire · 13 Aug 2026neutral

MiNK Therapeutics reported its financial results for the second quarter ended June 30, 2026, and provided an update on the clinical advancement of its lead candidate, agenT-797. The company also reported observations from a randomized Phase 2 trial of agenT-797 in acute lung injury.

Why it matters — The update provides INKT watchers with the company's latest financial position and new clinical data on its lead iNKT cell therapy candidate, agenT-797.

MiNK Therapeutics to Report Second Quarter 2026 Financial Results, Provide Clinical Updates on agenT-797 in Lung Injury, and Highlight Important Business Updates

GlobeNewsWire · 6 Aug 2026neutral

MiNK Therapeutics announced it will report its second quarter 2026 financial results before the market opens on Thursday, August 13, 2026, and will host a conference call and webcast at 8:30 AM ET that morning. The call will review financial results and provide a corporate update focused on the clinical advancement of its off-the-shelf allogeneic iNKT cell therapy agenT-797 in acute lung injury.

Why it matters — This item flags an upcoming investor update that will include clinical progress on agenT-797 in acute lung injury, a key program for MiNK.

FAQ

Frequently asked questions about INKT stock

What is the INKT stock price forecast for 2026-2027?

The 2 Wall Street analysts covering MiNK Therapeutics, Inc. have a median 12-month price target of $39, with estimates ranging from $35 to $43. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is INKT stock a buy right now?

Of the 2 analysts covering MiNK Therapeutics, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks MiNK Therapeutics, Inc. 38 out of 100 across roughly 4,600 US stocks as at 12 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank INKT?

As at 12 Aug 2026, MiNK Therapeutics, Inc. ranks 38 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (83 of 100).

Will INKT stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts implies +238.0% from the last close, and Ticker Nerd's factor model ranks MiNK Therapeutics, Inc. 38 out of 100 as at 12 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the INKT stock forecast for 2030?

No analyst covering MiNK Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for INKT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $35 to $43 over the next 12 months.

How has INKT stock performed over the past year?

MiNK Therapeutics, Inc. returned -18.7% over the 12 months to 12 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does MiNK Therapeutics, Inc. do?

MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in allogeneic invariant natural killer T (iNKT) cell therapies for cancer and immune-mediated diseases.

What is the latest news on INKT?

The most recent item we track (GlobeNewsWire, 13 Aug 2026): "MiNK Therapeutics Reports Second Quarter 2026 Financial Results and Reports Observations from Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury". MiNK Therapeutics reported its financial results for the second quarter ended June 30, 2026, and provided an update on the clinical advancement of its lead candidate, agenT-797. The company also reported observations from a randomized Phase 2 trial of agenT-797 in acute lung injury.

Company

About MiNK Therapeutics, Inc.

MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in allogeneic invariant natural killer T (iNKT) cell therapies for cancer and immune-mediated diseases. The company focuses on off-the-shelf, cryopreserved cell products designed to reconstitute and rebalance the immune system without the need for patient-specific manufacturing. Its lead candidate, agenT-797, is an allogeneic native iNKT cell therapy being evaluated in clinical trials for solid tumors, graft-versus-host disease, and severe pulmonary inflammation, including acute respiratory distress–type conditions. Alongside this flagship program, MiNK Therapeutics is advancing engineered iNKT candidates such as MiNK-215, targeting tumor stroma via FAP-CAR-iNKT, and MiNK-413, a CAR-iNKT therapy directed at B cell maturation antigen for immune and inflammatory settings. By bridging innate and adaptive immunity through its proprietary iNKT platform and scalable manufacturing processes, MiNK Therapeutics plays a specialized role in the biotechnology sector, aiming to provide “living drug” immunotherapies to address areas of high unmet medical need. Founded in 2017, the company is headquartered in New York, United States.

CEO Dr. Jennifer S. Buell Ph.D. · 15 employees · United States · https://minktherapeutics.com